Browse > Article
http://dx.doi.org/10.4014/jmb.1903.03009

Antidiabetic Drugs and Their Nanoconjugates Repurposed as Novel Antimicrobial Agents against Acanthamoeba castellanii  

Anwar, Ayaz (Department of Biological Sciences, School of Science and Technology, Sunway University)
Siddiqui, Ruqaiyyah (Department of Biological Sciences, School of Science and Technology, Sunway University)
Shah, Muhammad Raza (HEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi)
Khan, Naveed Ahmed (Department of Biological Sciences, School of Science and Technology, Sunway University)
Publication Information
Journal of Microbiology and Biotechnology / v.29, no.5, 2019 , pp. 713-720 More about this Journal
Abstract
Acanthamoeba castellanii belonging to the T4 genotype may cause a fatal brain infection known as granulomatous amoebic encephalitis, and the vision-threatening eye infection Acanthamoeba keratitis. The aim of this study was to evaluate the antiamoebic effects of three clinically available antidiabetic drugs, Glimepiride, Vildagliptin and Repaglinide, against A. castellanii belonging to the T4 genotype. Furthermore, we attempted to conjugate these drugs with silver nanoparticles (AgNPs) to enhance their antiamoebic effects. Amoebicidal, encystation, excystation, and host cell cytotoxicity assays were performed to unravel any antiacanthamoebic effects. Vildagliptin conjugated silver nanoparticles (Vgt-AgNPs) characterized by spectroscopic techniques and atomic force microscopy were synthesized. All three drugs showed antiamoebic effects against A. castellanii and significantly blocked the encystation. These drugs also showed significant cysticidal effects and reduced host cell cytotoxicity caused by A. castellanii. Moreover, Vildagliptin-coated silver nanoparticles were successfully synthesized and are shown to enhance its antiacanthamoebic potency at significantly reduced concentration. The repurposed application of the tested antidiabetic drugs and their nanoparticles against free-living amoeba such as Acanthamoeba castellanii described here is a novel outcome that holds tremendous potential for future applications against devastating infection.
Keywords
Acanthamoeba; antiparasitic; antidiabetic drugs; nanoparticles;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Illingworth CD, Cook SD, Karabatsas CH, Easty DL. 1995. Acanthamoeba keratitis: risk factors and outcome. Br. J. Ophthalmol. 79: 1078-1082.   DOI
2 Visvesvara GS, Moura H, Schuster FL. 2007. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immun. Med. Microbiol. 50: 1-26.   DOI
3 Khan NA. 2006. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol. Rev. 30: 564-595.   DOI
4 Lorenzo-Morales J, Khan NA, Walochnik J. 2015. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite 2015: 22: 10.   DOI
5 Coulon C, Collignon A, McDonnell G, Thomas V. 2010. Resistance of Acanthamoeba cysts to disinfection treatments used in health care settings. J. Clin. Microbiol. 48: 2689-2697.   DOI
6 Ortilles A, Belloc J, Rubio E, Fernandez MT, Benito M, Cristobal JA, et al. 2017. In-vitro development of an effective treatment for Acanthamoeba keratitis. Int. J. Antimicrob. Agents 50: 325-333.   DOI
7 Huh AJ, Kwon YJ. 2011. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Control. Release 156: 128-145.   DOI
8 Borase HP, Patil CD, Sauter IP, Rott MB, Patil SV. 2013. Amoebicidal activity of phytosynthesized silver nanoparticles and their in vitro cytotoxicity to human cells. FEMS Microbiol. Lett. 345: 127-131.   DOI
9 Imran M, Muazzam AG, Habib A, Matin A. 2016. Synthesis, characterization and amoebicidal potential of locally synthesized $TiO_2$ nanoparticles against pathogenic Acanthamoeba trophozoites in vitro. J. Photochem. Photobiol. B: Biol. 159: 125-132.   DOI
10 Baig MMFA, Khan S, Naeem MA, Khan GJ, Ansari MT. 2018. Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus. Biomed. Pharmacother. 97:1250-1258.   DOI
11 Malaisse WJ. 1999. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur. J. Clin. Invest. 29: 21-29.   DOI
12 De las Heras Alarcon C, Pennadam S, Alexander C. 2005. Stimuli responsive polymers for biomedical applications. Chem. Soc. Rev. 34: 276-285.   DOI
13 Al-Abdullah E, Al-Tuwaijri H, Hassan H, Al-Alshaikh M, Habib E, El-Emam A. 2015. Synthesis, antimicrobial and hypoglycemic activities of novel N-(1-adamantyl) carbothioamide derivatives. Molecules 20: 8125-8143.   DOI
14 Waghulde M, Naik J. 2017. Comparative study of encapsulated vildagliptin microparticles produced by spray drying and solvent evaporation technique. Drying Technol. 35: 1644-1654.   DOI
15 Baig AM, Iqbal J, Khan NA. 2013. In vitro efficacies of clinically available drugs against growth and viability of an Acanthamoeba castellanii keratitis isolate belonging to the T4 genotype. Antimicrob. Agents Chemother. 57: 3561-3567.   DOI
16 Baig AM, Zuberi H, Khan NA. 2014. Recommendations for the management of Acanthamoeba keratitis. J. Med. Microbiol. 63: 770-771.   DOI
17 Kumari A, Yadav SK, Yadav SC. 2010. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B: Biointerfaces 75: 1-8.   DOI
18 Sondi I, Salopek-Sondi B. 2004. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J. Colloids Interface Sci. 275: 177-182.   DOI
19 Seal DV. 2003. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye 17: 893-905.   DOI
20 Marciano-Cabral F, Cabral G. 2003. Acanthamoeba spp. as agents of disease in humans. Clin. Microbiol. Rev. 16: 273-307.   DOI
21 Masri A, Anwar A, Ahmed D, Siddiqui R, Shah MR, Khan N. 2018. Silver nanoparticle conjugation enhanced antibacterial efficacy of clinically approved drugs Cephradine and Vildagliptin. Antibiotics 7: 100.   DOI
22 Lakhundi S, Khan NA, Siddiqui R. 2014. Inefficacy of marketed contact lens disinfection solutions against keratitis-causing Acanthamoeba castellanii belonging to the T4 genotype. Exp. Parasitol. 141: 122-128.   DOI
23 Sissons J, Kim KS, Stins M, Jayasekera S, Alsam S, Khan NA. 2005. Acanthamoeba castellanii induces host cell death via a phosphatidylinositol 3-kinase-dependent mechanism. Infect. Immun. 73: 2704-2708.   DOI
24 Anwar A, Siddiqui R, Shah MR, Khan NA. 2018. Gold nanoparticle-conjugated cinnamic acid exhibits antiacanthamoebic and antibacterial properties. Antimicrob. Agents Chemother. 62: e00630-18.
25 Debnath A, Tunac JB, Silva-Olivares A, Galindo-Gomez S, Shibayama M, McKerrow JH. 2014. In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts. Antimicrob. Agents Chemother. 58: 1523-1528.   DOI
26 Campbell RK. 1998. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 32: 1044-1052.   DOI
27 Muller G. 2005. The mode of action of the antidiabetic drug glimepiride-beyond insulin secretion. Immunol. Endocr. Metab. Agents Med. Chem. 5: 499-518.   DOI
28 Abd El-Wahed M, El-Megharbel S, El-Sayed M, Zahran Y, Refat M. 2013. Synthesis of several new lanthanide Glimepiride complexes for evaluation of microbial activity. Russ. J. Gen. Chem. 83: 2438-2446.   DOI
29 Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. 2011. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes. Metab. 13: 775-783.   DOI
30 Willcox MD, Hume EB, Vijay AK, Petcavich R. 2010. Ability of silver-impregnated contact lenses to control microbial growth and colonisation. J. Optometry 3: 143-148.   DOI
31 Dudley R, Jarroll EL, Khan NA. 2009. Carbohydrate analysis of Acanthamoeba castellanii. Exp. Parasitol. 122: 338-343.   DOI
32 Aqeel Y, Siddiqui R, Anwar A, Shah MR, Khan NA. 2016. Gold nanoparticle conjugation enhances the antiacanthamoebic effects of chlorhexidine. Antimicrob. Agents Chemother. 60:1283-1288.   DOI
33 Anwar A, Siddiqui R, Shah MR, Khan NA. 2019. Gold nanoparticles conjugation enhances antiacanthamoebic properties of nystatin, fluconazole and amphotericin B. J. Microbiol. Biotechnol. 29: 171-177.   DOI
34 Anwar A, Khan NA, Siddiqui R, 2018. Combating Acanthamoeba spp. cysts: what are the options? Parasit. Vectors 11: 26.   DOI
35 Lorenzo-Morales J, Kliescikova J, Martinez-Carretero E, De Pablos LM, Profotova B, Nohynkova E, et al. 2008. Glycogen phosphorylase in Acanthamoeba spp.: determining the role of the enzyme during the encystment process using RNA interference. Eukaryot. Cell. 7: 509-517.   DOI
36 Abjani F, Khan NA, Yousuf FA, Siddiqui R. 2016. Targeting cyst wall is an effective strategy in improving the efficacy of marketed contact lens disinfecting solutions against Acanthamoeba castellanii cysts. Cont. Lens Anterior Eye 39: 239-243.   DOI
37 Sissons J, Alsam S, Stins M, Rivas AO, Morales JL, Faull J, et al. 2006. Use of in vitro assays to determine effects of human serum on biological characteristics of Acanthamoeba castellanii. J. Clin. Microbiol. 44: 2595-2600.   DOI
38 Anwar A, Siddiqui R, Hussain MA, Ahmed D, Shah MR, Khan NA. 2018. Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole. Parasitol. Res. 117: 265-271.   DOI